Could BridgeBio really be worth $400? Even with some conservative assumptions, the combination of Attruby’s main indication, the pipeline, and the ACT Early trial could add up to a very large valuation.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit atticusanalysis.substack.com